Robert Califf, MD, current deputy commissioner for medical products and tobacco at the FDA, has been nominated to lead the FDA and take over as commissioner. Margaret Hamburg, MD, stepped down from the position in February after nearly 6 years at the helm.
President Barack Obama has announced his nomination to lead the FDA: Robert Califf, MD, the current deputy commissioner for medical products and tobacco at the FDA. If the Senate confirms the nomination, Dr Califf would take the reins as the new commissioner for food and drugs.
In February, Margaret Hamburg, MD, announced she was stepping down, and since then Stephen Ostroff, MD, the FDA's chief scientist has filled the position. At the time, there had been speculation when Dr Califf's appointment with the FDA was first announced in January 2015 that he was part of the FDA's succession plan and would eventually become the next FDA commissioner.
“Dr Califf’s deep knowledge and experience in the areas of medicine and clinical research will enable the agency to capitalize on, and improve upon, the significant advances we’ve made in medical product development and regulation over the last few years,” Dr Hamburg had
said in a statement upon Dr Califf’s appointment as deputy commissioner.
Dr Califf has spent most of his career in academia, having spent more than 30 years as a prominent cardiologist and medical researcher at Duke University. However, he has some experience with the FDA, having served on the agency's Cardiorenal Advisory Panel from 1996 to 2000 and its Science Board Working Group from 2007 to 2008.
Among the issues Dr Califf will have to tackle as commissioner are unfinished tobacco regulations, food safety and labeling reforms, and pressure from Republicans in Congress to streamline drug reviews.
The White House announced the nomination Tuesday along with a number of other officials being nominated for various federal positions.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Understanding How Fitness Affects Digestive Diseases
April 18th 2025Exercise is a powerful modulator of gut health in patients with gastrointestinal (GI) conditions, as moderate activity can ease gut inflammation, reduce colorectal cancer risk, and relieve constipation, while intense workouts may backfire, causing reflux, GI bleeding, or gut barrier disruption.
Read More
FDA Greenlights Dupilumab for Chronic Spontaneous Urticaria, Marking First Approval in a Decade
April 18th 2025Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives and itching remain uncontrolled by antihistamines.
Read More